Clinical prediction of Parkinson's disease: planning for the age of neuroprotection
Identifieur interne : 000395 ( PascalFrancis/Corpus ); précédent : 000394; suivant : 000396Clinical prediction of Parkinson's disease: planning for the age of neuroprotection
Auteurs : R. B. Postuma ; J. F. Gagnon ; J. MontplaisirSource :
- Journal of neurology, neurosurgery and psychiatry [ 0022-3050 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
As a chronic progressive disease, Parkinson's disease (PD) has a presymptomatic interval; that is, a period during which the pathological process has begun, but motor signs required for the clinical diagnosis are absent. The ability to identify this preclinical stage may be critical in the development and eventual use of neuroprotective therapy. Recently proposed staging systems of PD have suggested that degeneration may occur initially in areas outside the substantia nigra, suggesting that non-motor manifestations may be markers of presymptomatic PD. Decreased olfaction has recently been demonstrated to predict PD in prospective pathological studies, although the lead time may be relatively short, and the positive predictive value is low. Idiopathic RBD has a very high predictive value, with approximately 50% of affected individuals developing PD or dementia within 10 years. This implies that idiopathic RBD patients are ideal candidates to test potential preclinical markers. However, the specificity of symptom screens for RBD is not established, not all persons with PD develop RBD, and there are only limited ways to predict which RBD patients will develop PD. Other simple screens based upon autonomic symptoms, depression and personality changes, quantitative motor testing and other sleep disorders may also be useful markers, but have not been extensively tested. Other more expensive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, dopaminergic imaging and transcranial ultrasound may be especially useful in defining disease risk in those identified through primary screening.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 10-0428860 INIST |
|---|---|
| ET : | Clinical prediction of Parkinson's disease: planning for the age of neuroprotection |
| AU : | POSTUMA (R. B.); GAGNON (J. F.); MONTPLAISIR (J.) |
| AF : | Department of Neurology, McGill University, Montreal General Hospital/Montreal, Quebec/Canada (1 aut.); Centre d'etude du sommeil, Hopital du Sacre-Coeur/Montreal/Canada (1 aut., 2 aut., 3 aut.); Département de psychiatrie, Université de Montréal/Canada (2 aut., 3 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Journal of neurology, neurosurgery and psychiatry; ISSN 0022-3050; Coden JNNPAU; Royaume-Uni; Da. 2010; Vol. 81; No. 9; Pp. 1008-1013; Bibl. 76 ref. |
| LA : | Anglais |
| EA : | As a chronic progressive disease, Parkinson's disease (PD) has a presymptomatic interval; that is, a period during which the pathological process has begun, but motor signs required for the clinical diagnosis are absent. The ability to identify this preclinical stage may be critical in the development and eventual use of neuroprotective therapy. Recently proposed staging systems of PD have suggested that degeneration may occur initially in areas outside the substantia nigra, suggesting that non-motor manifestations may be markers of presymptomatic PD. Decreased olfaction has recently been demonstrated to predict PD in prospective pathological studies, although the lead time may be relatively short, and the positive predictive value is low. Idiopathic RBD has a very high predictive value, with approximately 50% of affected individuals developing PD or dementia within 10 years. This implies that idiopathic RBD patients are ideal candidates to test potential preclinical markers. However, the specificity of symptom screens for RBD is not established, not all persons with PD develop RBD, and there are only limited ways to predict which RBD patients will develop PD. Other simple screens based upon autonomic symptoms, depression and personality changes, quantitative motor testing and other sleep disorders may also be useful markers, but have not been extensively tested. Other more expensive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, dopaminergic imaging and transcranial ultrasound may be especially useful in defining disease risk in those identified through primary screening. |
| CC : | 002B17; 002B17G |
| FD : | Maladie de Parkinson; Pathologie du système nerveux; Prédiction; Planification |
| FG : | Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central |
| ED : | Parkinson disease; Nervous system diseases; Prediction; Planning |
| EG : | Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease |
| SD : | Parkinson enfermedad; Sistema nervioso patología; Predicción; Planificación |
| LO : | INIST-6015.354000194258840150 |
| ID : | 10-0428860 |
Links to Exploration step
Pascal:10-0428860Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Clinical prediction of Parkinson's disease: planning for the age of neuroprotection</title><author><name sortKey="Postuma, R B" sort="Postuma, R B" uniqKey="Postuma R" first="R. B." last="Postuma">R. B. Postuma</name><affiliation><inist:fA14 i1="01"><s1>Department of Neurology, McGill University, Montreal General Hospital</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Centre d'etude du sommeil, Hopital du Sacre-Coeur</s1><s2>Montreal</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gagnon, J F" sort="Gagnon, J F" uniqKey="Gagnon J" first="J. F." last="Gagnon">J. F. Gagnon</name><affiliation><inist:fA14 i1="02"><s1>Centre d'etude du sommeil, Hopital du Sacre-Coeur</s1><s2>Montreal</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Département de psychiatrie, Université de Montréal</s1><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Montplaisir, J" sort="Montplaisir, J" uniqKey="Montplaisir J" first="J." last="Montplaisir">J. Montplaisir</name><affiliation><inist:fA14 i1="02"><s1>Centre d'etude du sommeil, Hopital du Sacre-Coeur</s1><s2>Montreal</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Département de psychiatrie, Université de Montréal</s1><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0428860</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0428860 INIST</idno><idno type="RBID">Pascal:10-0428860</idno><idno type="wicri:Area/PascalFrancis/Corpus">000395</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Clinical prediction of Parkinson's disease: planning for the age of neuroprotection</title><author><name sortKey="Postuma, R B" sort="Postuma, R B" uniqKey="Postuma R" first="R. B." last="Postuma">R. B. Postuma</name><affiliation><inist:fA14 i1="01"><s1>Department of Neurology, McGill University, Montreal General Hospital</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Centre d'etude du sommeil, Hopital du Sacre-Coeur</s1><s2>Montreal</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gagnon, J F" sort="Gagnon, J F" uniqKey="Gagnon J" first="J. F." last="Gagnon">J. F. Gagnon</name><affiliation><inist:fA14 i1="02"><s1>Centre d'etude du sommeil, Hopital du Sacre-Coeur</s1><s2>Montreal</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Département de psychiatrie, Université de Montréal</s1><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Montplaisir, J" sort="Montplaisir, J" uniqKey="Montplaisir J" first="J." last="Montplaisir">J. Montplaisir</name><affiliation><inist:fA14 i1="02"><s1>Centre d'etude du sommeil, Hopital du Sacre-Coeur</s1><s2>Montreal</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Département de psychiatrie, Université de Montréal</s1><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Journal of neurology, neurosurgery and psychiatry</title><title level="j" type="abbreviated">J. neurol. neurosurg. psychiatry</title><idno type="ISSN">0022-3050</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of neurology, neurosurgery and psychiatry</title><title level="j" type="abbreviated">J. neurol. neurosurg. psychiatry</title><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term><term>Parkinson disease</term><term>Planning</term><term>Prediction</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Prédiction</term><term>Planification</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As a chronic progressive disease, Parkinson's disease (PD) has a presymptomatic interval; that is, a period during which the pathological process has begun, but motor signs required for the clinical diagnosis are absent. The ability to identify this preclinical stage may be critical in the development and eventual use of neuroprotective therapy. Recently proposed staging systems of PD have suggested that degeneration may occur initially in areas outside the substantia nigra, suggesting that non-motor manifestations may be markers of presymptomatic PD. Decreased olfaction has recently been demonstrated to predict PD in prospective pathological studies, although the lead time may be relatively short, and the positive predictive value is low. Idiopathic RBD has a very high predictive value, with approximately 50% of affected individuals developing PD or dementia within 10 years. This implies that idiopathic RBD patients are ideal candidates to test potential preclinical markers. However, the specificity of symptom screens for RBD is not established, not all persons with PD develop RBD, and there are only limited ways to predict which RBD patients will develop PD. Other simple screens based upon autonomic symptoms, depression and personality changes, quantitative motor testing and other sleep disorders may also be useful markers, but have not been extensively tested. Other more expensive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, dopaminergic imaging and transcranial ultrasound may be especially useful in defining disease risk in those identified through primary screening.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-3050</s0></fA01><fA02 i1="01"><s0>JNNPAU</s0></fA02><fA03 i2="1"><s0>J. neurol. neurosurg. psychiatry</s0></fA03><fA05><s2>81</s2></fA05><fA06><s2>9</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Clinical prediction of Parkinson's disease: planning for the age of neuroprotection</s1></fA08><fA11 i1="01" i2="1"><s1>POSTUMA (R. B.)</s1></fA11><fA11 i1="02" i2="1"><s1>GAGNON (J. F.)</s1></fA11><fA11 i1="03" i2="1"><s1>MONTPLAISIR (J.)</s1></fA11><fA14 i1="01"><s1>Department of Neurology, McGill University, Montreal General Hospital</s1><s2>Montreal, Quebec</s2><s3>CAN</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Centre d'etude du sommeil, Hopital du Sacre-Coeur</s1><s2>Montreal</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="03"><s1>Département de psychiatrie, Université de Montréal</s1><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ></fA14><fA20><s1>1008-1013</s1></fA20><fA21><s1>2010</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>6015</s2><s5>354000194258840150</s5></fA43><fA44><s0>0000</s0><s1>© 2010 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>76 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>10-0428860</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Journal of neurology, neurosurgery and psychiatry</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>As a chronic progressive disease, Parkinson's disease (PD) has a presymptomatic interval; that is, a period during which the pathological process has begun, but motor signs required for the clinical diagnosis are absent. The ability to identify this preclinical stage may be critical in the development and eventual use of neuroprotective therapy. Recently proposed staging systems of PD have suggested that degeneration may occur initially in areas outside the substantia nigra, suggesting that non-motor manifestations may be markers of presymptomatic PD. Decreased olfaction has recently been demonstrated to predict PD in prospective pathological studies, although the lead time may be relatively short, and the positive predictive value is low. Idiopathic RBD has a very high predictive value, with approximately 50% of affected individuals developing PD or dementia within 10 years. This implies that idiopathic RBD patients are ideal candidates to test potential preclinical markers. However, the specificity of symptom screens for RBD is not established, not all persons with PD develop RBD, and there are only limited ways to predict which RBD patients will develop PD. Other simple screens based upon autonomic symptoms, depression and personality changes, quantitative motor testing and other sleep disorders may also be useful markers, but have not been extensively tested. Other more expensive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, dopaminergic imaging and transcranial ultrasound may be especially useful in defining disease risk in those identified through primary screening.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Prédiction</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Prediction</s0><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Predicción</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Planification</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Planning</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Planificación</s0><s5>10</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>277</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 10-0428860 INIST</NO><ET>Clinical prediction of Parkinson's disease: planning for the age of neuroprotection</ET><AU>POSTUMA (R. B.); GAGNON (J. F.); MONTPLAISIR (J.)</AU><AF>Department of Neurology, McGill University, Montreal General Hospital/Montreal, Quebec/Canada (1 aut.); Centre d'etude du sommeil, Hopital du Sacre-Coeur/Montreal/Canada (1 aut., 2 aut., 3 aut.); Département de psychiatrie, Université de Montréal/Canada (2 aut., 3 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Journal of neurology, neurosurgery and psychiatry; ISSN 0022-3050; Coden JNNPAU; Royaume-Uni; Da. 2010; Vol. 81; No. 9; Pp. 1008-1013; Bibl. 76 ref.</SO><LA>Anglais</LA><EA>As a chronic progressive disease, Parkinson's disease (PD) has a presymptomatic interval; that is, a period during which the pathological process has begun, but motor signs required for the clinical diagnosis are absent. The ability to identify this preclinical stage may be critical in the development and eventual use of neuroprotective therapy. Recently proposed staging systems of PD have suggested that degeneration may occur initially in areas outside the substantia nigra, suggesting that non-motor manifestations may be markers of presymptomatic PD. Decreased olfaction has recently been demonstrated to predict PD in prospective pathological studies, although the lead time may be relatively short, and the positive predictive value is low. Idiopathic RBD has a very high predictive value, with approximately 50% of affected individuals developing PD or dementia within 10 years. This implies that idiopathic RBD patients are ideal candidates to test potential preclinical markers. However, the specificity of symptom screens for RBD is not established, not all persons with PD develop RBD, and there are only limited ways to predict which RBD patients will develop PD. Other simple screens based upon autonomic symptoms, depression and personality changes, quantitative motor testing and other sleep disorders may also be useful markers, but have not been extensively tested. Other more expensive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, dopaminergic imaging and transcranial ultrasound may be especially useful in defining disease risk in those identified through primary screening.</EA><CC>002B17; 002B17G</CC><FD>Maladie de Parkinson; Pathologie du système nerveux; Prédiction; Planification</FD><FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central</FG><ED>Parkinson disease; Nervous system diseases; Prediction; Planning</ED><EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG><SD>Parkinson enfermedad; Sistema nervioso patología; Predicción; Planificación</SD><LO>INIST-6015.354000194258840150</LO><ID>10-0428860</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000395 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000395 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:10-0428860
|texte= Clinical prediction of Parkinson's disease: planning for the age of neuroprotection
}}
| This area was generated with Dilib version V0.6.29. |  |